AIIMS Delhi to start screening kids aged 6-12 years for COVAXIN trials

The All India Institute of Medical Sciences (AIIMS) in Delhi will start recruitment for clinical trials tomorrow onwards for the children who are in the age group of 6-12 years, news agency ANI reported.

It further said that clinical trial of children of the 2-6 age group will start after that.

Earlier, the screening of children for the trial of single-dose Covaxin, India’s first indigenously developed COVID-19 vaccine, among those aged between 2 and 18 started at the AIIMS in New Delhi on 7 June and is over.

The trial on children has already started at AIIMS Patna to see if the Bharat Biotech jab is suitable for children. Participants would be given the vaccine after their screening report comes.

India’s drug regulator had granted permission for conducting the Phase 2/3 clinical trial of Covaxin in the age group 2 to 18 years on May 12. Covaxin is being used on adults in India’s ongoing COVID-19 vaccination drive. The government last week cautioned that even though COVID-19 has not taken a serious shape among children till now, its impact can increase among them if there is a change in virus behaviour or epidemiology dynamics, and said preparations are being strengthened to deal with any such situation.

A national expert group has been formed to review COVID-19 infections in children and approach the pandemic in a renewed way to strengthen the nation’s preparedness, NITI Aayog Member (Health) V.K. Paul had said at a press conference.

The group has examined signs which were not available four-five months before, he said.

It has also considered available data, clinical profile, the country’s experience, disease dynamics, nature of the virus and the pandemic and has come up with guidelines, which will be publicly released soon.

“While we have been systematically reviewing scientific developments in this area, the group has been formed to take an updated view of the situation,” Mr Paul said.

Asked if the Pfizer vaccine, if it comes to India, will be considered for children between the age of 12 and 15 years as being approved by the U.K., Mr Paul had said that the country has its own vaccines which are being readied for children. 

“Child cohort is not a small cohort. My rough guess is that if it is between 12 to 18 years, this itself is about 13 to 14 crore population and for which we will need about 25-26 crore doses. “We cannot have some people getting and others not getting. So we will have to take this into account when we strategise and make a decision based on how many doses of which vaccines are available,” he said.

He further shared that Zydus Cadila’s vaccine is already being tested in children.
Subscribe to our newsletter
Subscribe to our newsletter
Sign up here to get the latest news delivered directly to your inbox.
You can unsubscribe at any time

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More